Research

Current Research Studies

ENDEAVOR IV

A randomized, controlled trial of the Medtronic Endeavor Drug Eluting coronary artery stent system versus the TAXUS paclitaxel-eluting coronary stent system in de Novo native coronary artery lesions.

HORIZONS

A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine GPIIb/IIIa inhibition with bivalirudin and bail-out GPIIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow-release paclitaxel-eluting stent (TAXUS) or an otherwise identical uncoated bare metal stent (Express).

IMPROVE-IT

A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (ezetimibe/simvastatin) vs Simvastatin Monotherapy in High-Risk Patients Presenting with Acute Coronary Syndrome.

ENDEAVOR IV PK

Evaluation of Pharmacokinetics (PK) and safety of the Medtronic Endeavor Drug (ABT-578) Eluting coronary artery stent system in de Novo native coronary artery lesions.

RED-HF/AMGEN

A double-blind, randomized, placebo-controlled, multi-center study to access the efficacy and safety of darbepoetin alfa treatment on the mortality and morbidity in heart failure subjects with symptomatic left ventricular systolic dysfunction and anemia.

PRECISION

A randomized, double-blind, parallel-group study of cardiovascular safety in osteoarthritis or rheumatoid arthritis patients with or at high risk for cardiovascular disease comparing celecoxib with naproxen and ibuprofen.

TRA-2P

A multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH530348 in addition to standard of care in subjects with a history of atherosclerotic disease: thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events.

ENDEAVOR SVS

A trial of the Medtronic Endeavor Drug (ABT-578) Eluting coronary artery stent system in small vessels de Novo native coronary artery lesions.

GRAVATIS

Gauging Responsiveness with A Verifynow assay- Impact on Thrombosis And Safety.

XIENCE V USA

Everolimus Eluting Coronary Stent System USA Post Approval Study to evaluate patient compliance with adjunctive antiplatelet therapy and major bleeding complications, and to determine clinical device and procedural success during commercial use.

XIENCE V- PART II

Everolimus Eluting Coronary Stent System USA Post Approval Study to evaluate patient compliance with adjunctive antiplatelet therapy and major bleeding complications, and to determine clinical device and procedural success during commercial use.

XIENCE DAPT

XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study. The Study will also assess the safety and effectiveness of 12 versus 30 months of blood thinning medicines in patients who are implanted with XIENCE V EECSS.

PROTECT

Prospective, multicenter, randomized, two-arm, open-label trial to compare stent thrombosis rate of the Endeavor Zotarolimas Eluting Coronary Stent in a patient population requiring stent implantation.

ENGAGE AF-TIMI 48

Oral Factor Xa inhibitor in patients with atrial fibrillation.

COMPLETE SFA

Stenting of lesions in the superficial femoral arteries and popliteal arteries using the complete SE stent.

RESOLUTE US

A clinical evaluation of the Medtronic Endeavor Resolute Zotarolimus-Eluting Coronary Artery Stent System in the treatment of De Novo lesions in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.2 mm

PROTECT CA

Continued access study – Patient related outcomes with Endeavor stenting trial.

APPRAISE 2

A phase 3, randomized, double-blind, evaluation of the safety and efficacy of Apixaban in subjects with a recent acute coronary syndrome

SPIRIT

A Clinical Evaluation of the XIENCE PRIME™ and XIENCE PRIME ™ LL Everolimus Eluting Coronary Stent System

BRIDGE

Maintenance of platelet inhiBition with cangreloR after dIscontinuation of thienopyriDines in patients undergoing surGEry: The BRIDGE trial.

HCRI DAPT

A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.

PEGASUS

Assess prevention of thrombotic events with ticagrelor versus placebo

EXCEL

Unprotected left main occlusion - cardiac surgery vs stenting.

EDUCATE

Endeavor Drug eluting stenting: Understanding Care Antiplatelet agents and Thrombotic Events.

POZEN

A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers.

CHAMPION PHOENIX

A Clinical Trial Comparing Cangelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention.

CHOICE

Carotid Stenting For High Surgical Risk Patients; Evaluating Outcomes Through The CollectIon Of Clinical Evidence ("CHOICE").

» Owner Login